The development of innovative drug molecules stands as a crucial pillar in the current global competition in science and technology. This endeavor profoundly influences economic growth and societal advancement. More than 60% of active pharmaceutical ingredients are almost exclusively orally administered. The popularity of the oral route correlates with their noninvasive nature, patient compliance, and convenience, therefore; it must be addressed as a focal point in drug development research.
However, the dissolution of drugs in the gastrointestinal tract is a prerequisite for absorption, and thus, poses substantial challenges for oral administration. Therefore, enhancing the bioavailability of oral medications is a crucial issue. “Though there are a number of companies working in specific technologies and strategies for specific drug types, there is a shortage in those offering integrated formulations and boosting techniques that can be offered seamlessly to customers. Research needs to increase the focus on combining solubility enhancement along with drug stabilization and targeting techniques to improve bioavailability especially that 40% of drugs are of hydrophobic nature” stated Dr. Nader Khedr, Chairman of the Board-RX Healthcare LLC FZ-Dubai.
“Taken into consideration that the aim of pharmaceutical and biotech industry today is minimizing systemic exposure and maximizing concentration at the target site, so that smaller doses can be given at less frequent intervals to improve patient compliance due to better therapeutic performance and reduced toxicity, as well as aiding drug developers in significantly reducing the time and cost of development and easing the regulatory approval process” remarked Dr. Nader.
A number of Bioavailability enhancement strategies, such as, liposomal formulations, Nano scale size reduction and others were developed within an integrated range of formulations and delivery strategies by various pharmaceutical companies. When asked about the strategy of his companies, he declared “RX Healthcare group is a leader company in Dubai, Egypt and MENA region that offers new innovative Italian products designed by targeting techniques for boosting bioavailability. FM-Matrix (Formula Modulation Matrix) technology is an innovative nutrition-friendly technology owned by RX Healthcare group which has been designed and developed to enhance solubility, bioavailability and enteric absorption of substances with low solubility in water. It assures the maximum biological efficacy, safety and stability for products prepared with the least used dose for better life quality”.
Dr. Nader mentioned “RX Healthcare group was able to deliver new advanced formulas prepared by FM-Matrix technology to the Egyptian market ensuring better bioavailability and best effectiveness. The list of these products includes: Neopausil, Kiddo3 and Novoferr.
Neopausil is a dietary supplement based on Resveratrol, Vitamin E and Vitamin D3 used as anti-inflammatory, antioxidant, immune booster and anti-aging.
Kiddo3 is a vitamin D3 dietary supplement for teeth, bone and immunity support. Novoferr is the first liquid liposomal iron in the market for treatment of iron deficiency.
RX Healthcare group will continue bringing more and more potential innovative molecules to the Egyptian market aiming for better life for everyone”.
Discussion about this post